vero
cell
maintain
dulbecco
modifi
eagl
medium
dmem
fetal
bovin
serum
fb
previous
describ
et
al
human
clinic
patient
isol
describ
previous
use
experi
biosafeti
level
facil
special
infecti
agent
unit
siau
king
fahd
medic
research
center
kfmrc
king
abdulaziz
univers
kau
jeddah
saudi
arabia
apheresi
platelet
unit
donor
plasma
ml
platelet
per
unit
collect
king
abdulaziz
univers
hospit
kauh
transfus
servic
jeddah
kingdom
saudi
arabia
voluntari
donor
use
apheresi
collect
unit
terumo
bct
japan
platelet
store
continu
agit
platelet
unit
screen
routin
hiv
htlv
syphili
well
hcv
hbv
hiv
nat
donor
also
confirm
neg
antibodi
baselin
sampl
remain
volum
ml
remain
platelet
count
four
unit
platelet
use
studi
platelet
unit
inocul
stock
dilut
platelet
unit
treat
intercept
larg
volum
process
set
intercept
illumin
ceru
corpor
usa
residu
amotosalen
free
photoproduct
remov
use
integr
compound
adsorpt
devic
accord
manufactur
instruct
follow
sampl
collect
test
posit
control
sampl
viru
stock
neg
control
sampl
platelet
inocul
viru
sampl
inocul
platelet
sampl
treat
platelet
intercept
treatment
fig
sampl
store
test
detect
replic
platelet
perform
previous
describ
minor
modif
pinna
et
al
hindawi
et
al
briefli
collect
inactiv
sampl
dilut
dilut
dmem
fb
contain
heparin
sulphat
uml
inocul
vero
cell
plate
duplic
incub
h
inoculum
remov
replac
ml
dmem
fb
incub
day
day
three
supernat
collect
plate
dilut
dmem
fb
vero
cell
two
success
passag
supernat
collect
passag
also
use
viral
load
quantif
quantit
revers
transcript
polymeras
chain
reaction
experi
plate
maintain
nine
day
inocul
observ
cytopath
effect
cpe
ensur
absenc
residu
infecti
virus
plaqu
assay
perform
previous
describ
hindawi
et
al
minor
modif
briefli
sampl
serial
dilut
dmem
fb
contain
heparin
sulphat
uml
start
ml
dilut
inocul
confluent
vero
cell
monolay
incub
h
inoculum
remov
replac
overlay
media
dmem
agaros
incub
day
incub
cell
stain
neutral
red
h
plaqu
count
calcul
titr
unit
pfu
ml
viral
rna
extract
sampl
collect
directli
platelet
unit
posit
neg
sampl
well
cell
supernat
use
qiagen
viral
rna
mini
kit
qiagen
germani
accord
manufactur
instruct
rel
quantif
viral
load
perform
previous
describ
hashem
et
al
modif
brief
conduct
use
primer
probe
target
upstream
region
e
gene
upe
quantitect
probe
kit
qiagen
germani
appli
biosystem
fast
pcr
system
ct
valu
replic
sampl
analys
ct
valu
standard
curv
known
mrna
copi
number
viral
load
express
equival
equival
per
ml
compar
sampl
run
includ
posit
viral
templat
control
neg
control
sampl
test
duplic
mean
report
studi
approv
biomed
ethic
committe
unit
king
abdulaziz
univers
hospit
approv
spike
four
unit
human
platelet
collect
healthi
donor
spike
unit
treat
amotosalen
uva
light
mean
infecti
viral
titr
sampl
four
unit
pfuml
rang
pfuml
tabl
treatment
spike
unit
result
mean
reduct
pfuml
infecti
viru
detect
plaqu
assay
tabl
fig
show
repres
plaqu
assay
result
test
unit
expect
test
neg
control
sampl
collect
spike
show
viru
note
viral
infect
titr
posit
control
mean
pfuml
rang
pfuml
reduc
pfuml
rang
pfuml
spike
platelet
unit
lower
expect
dilut
log
previous
observ
plasma
hindawi
et
al
suggest
platelet
andor
plasma
may
impact
infect
titr
probabl
due
inhibit
use
sampl
neg
antibodi
confirm
result
viral
genom
titr
determin
collect
sampl
shown
tabl
posit
control
sampl
unit
equival
infecti
viral
titr
determin
plaqu
assay
shown
tabl
importantli
sampl
show
viral
genom
titr
slightli
reduc
compar
titr
sampl
result
suggest
amotosalen
uva
light
inactiv
infecti
virus
without
signific
effect
viral
genom
titr
shown
dengu
viru
zika
viru
musso
et
al
santa
maria
et
al
hindawi
et
al
exclud
possibl
residu
replic
associ
presenc
viral
genom
titr
treat
platelet
unit
tabl
inocul
collect
sampl
vero
cell
evalu
infect
three
success
passag
although
cultur
sampl
show
complet
cpe
within
day
similar
posit
control
cpe
observ
cell
inocul
inactiv
sampl
similar
neg
mock
control
fig
even
nine
day
incub
three
passag
confirm
determin
viral
genom
titr
supernat
collect
passag
inocul
either
sampl
shown
tabl
passag
sampl
led
viral
replic
increas
viral
titr
upon
passag
hand
viral
infect
titr
cell
inocul
inactiv
sampl
decreas
lower
undetect
level
cultur
supernat
togeth
data
confirm
complet
inactiv
test
platelet
unit
absenc
viru
outbreak
emerg
pathogen
pose
high
risk
blood
safeti
screen
test
often
avail
occurr
spread
impact
difficult
predict
make
hard
implement
safeti
measur
appropri
time
manner
recent
chikungunya
viru
outbreak
itali
sever
impact
blood
avail
lazio
region
caus
offici
demand
halt
platelet
suppli
centr
region
intercept
technolog
implement
allow
continu
platelet
product
prepar
could
thu
prevent
complet
stop
platelet
suppli
support
hospit
entir
region
vairo
et
al
italian
outbreak
second
ravenna
outbreak
yet
anoth
exampl
recent
emerg
arboviru
outbreak
mediterranean
like
enabl
spread
vector
due
global
warm
increas
intern
travel
good
exchang
zika
viru
outbreak
south
central
america
anoth
exampl
high
number
asymptomat
carrier
made
difficult
protect
blood
suppli
lanteri
et
al
although
best
knowledg
transmiss
blood
transfus
yet
report
detect
genom
rna
blood
infect
patient
rais
concern
blood
safeti
stramer
viral
genom
rna
detect
plasma
serum
patient
outbreak
saudi
arabia
south
korea
give
rise
concern
potenti
transmiss
blood
transfus
viral
load
log
genom
copi
per
ml
whole
blood
log
genom
copi
per
ml
serum
report
south
korea
kim
et
al
viral
load
log
genom
copi
per
ml
correspond
log
infecti
viru
serum
also
report
outbreak
saudi
arabia
corman
et
al
although
report
transmiss
far
viral
rna
could
detect
patient
blood
almost
two
week
corman
et
al
may
repres
possibl
rout
transmiss
especi
sever
studi
shown
replic
sever
blood
cell
chu
et
al
zhou
et
al
furthermor
aabb
list
pathogen
concern
blood
safeti
stramer
therefor
import
investig
possibl
way
reduc
risk
transmiss
avoid
effect
blood
suppli
especi
endem
region
saudi
arabia
could
lead
deferr
donat
confirm
suspect
case
happen
outbreak
http
wwwwhointcsrsarsguidelinesbloodsafetyen
previous
describ
inactiv
spike
human
plasma
sampl
hindawi
et
al
averag
log
reduct
infecti
titr
amotosalenuva
treatment
studi
report
mean
log
reduct
infecti
titr
platelet
sampl
indic
amotosalenuva
treatment
platelet
effect
inactiv
viru
potenti
reduc
risk
transmiss
contamin
platelet
unit
reduct
least
one
log
higher
possibl
infecti
titr
serum
report
previous
corman
et
al
note
inactiv
mechan
intercept
treatment
depend
nucleic
acid
strand
therebi
prevent
pathogen
replic
given
size
amplicon
detect
viral
genom
rna
still
possibl
inactiv
genom
titr
slightli
affect
pathogen
inactiv
treatment
find
unusu
previous
report
success
inactiv
virus
specif
amotosalenuva
light
inactiv
process
result
pathogen
nucleic
acid
strand
manner
adduct
form
nucleic
acid
thu
inhibit
transcript
replic
howev
necessarili
site
target
thu
treatment
expect
affect
viral
replic
nucleic
acid
remain
detect
explain
genom
titr
reduc
similar
fashion
infect
reduct
nonetheless
addit
safeti
assess
presenc
residu
particl
inactiv
platelet
unit
passag
three
success
time
three
day
show
cpe
inactiv
unit
viral
genom
also
detect
nine
day
three
passag
show
loss
particl
passag
confirm
total
inactiv
viral
particl
treat
platelet
unit
one
major
limit
studi
use
four
human
platelet
unit
subsequ
studi
includ
larger
number
sampl
although
addit
amotosalen
alon
without
uva
light
reduc
viral
titr
spike
sampl
data
shown
effect
adsorpt
step
alon
without
amotosalen
uva
light
test
studi
includ
subsequ
work
determin
effect
step
inactiv
process
addit
futur
studi
also
investig
possibl
effect
amotosalen
uva
light
treatment
viral
particl
inactiv
may
also
occur
via
path
directli
associ
genom
alter
coval
viral
protein
oxid
reaction
induc
singlet
oxygen
gener
process
furthermor
possibl
viru
attach
adher
platelet
even
internalis
platelet
test
nonetheless
data
show
whole
inactiv
process
effect
reduc
risk
viru
transmiss
via
transfus
recent
studi
report
reduct
log
spike
platelet
prepar
pa
plasma
use
uvc
light
eickmann
et
al
addit
minimum
reduct
log
plasma
report
use
methylen
blue
visibl
light
eickmann
et
al
riboflavin
uv
light
keil
et
al
respect
although
report
shown
mark
reduct
infecti
viral
titr
repres
accept
safeti
margin
accord
european
committe
blood
transfus
presenc
remain
low
level
viru
treatment
investig
confirm
complet
inactiv
viru
addit
would
interest
observ
effect
inactiv
treatment
genom
viral
load
correl
result
mean
genom
titr
patient
studi
show
effici
inactiv
isol
spike
human
platelet
concentr
plasma
amotosalenuva
complet
inactiv
mean
log
reduct
viral
titr
confirm
passag
experi
exclud
remain
particl
technolog
repres
effici
method
reduc
possibl
risk
associ
well
virus
may
transmit
via
blood
transfus
qa
mpm
employe
ceru
corpor
author
compet
interest
